Korsuva

Small-cap biotech Cara Therapeutics Inc (NASDAQ: CARA) is trading to its highest level since early April after it released the results of a Phase 3 trial for its lead candidate Korsuva. What Happened Cara, which focuses on developing new chemical entities for treating pruritus,  a...

Cara Therapeutics Inc (NASDAQ: CARA) got some love from Wall Street on Tuesday, with one analyst projecting significant upside for the stock based the outlook for its leading drug candidate. The Analyst Bank of America Merrill Lynch analyst Jason Gerberry initiated coverage of Cara with a Neutral...